BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

PTC, Roche deal

Roche received exclusive, worldwide rights to PTC's spinal muscular atrophy (SMA) program, which includes three small molecules in preclinical testing and potential backup compounds. PTC will receive $30 million up front, and is eligible for up to $460 million...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >